MDNews - Cleveland-Akron-Canton

November/December 2015

Issue link: http://viewer.e-digitaledition.com/i/589857

Contents of this Issue

Navigation

Page 9 of 43

for a full genomic profile that identifies the molecular drivers behind the cancer. "Every tumor is unique," says Dr. Rush. "If you can understand what makes a given tumor different, you can use that information to plan a patient's therapy. This is what we mean by personal- ized medicine." Having a patient's genomic profile also allows doctors to search for clinical trials that may offer a new treatment approach when there are no proven options. "We can look at a patient's gene muta- tions and try to find a clinical trial that may be most beneficial based on that data," says Dr. Rush. Akron Children's is collaborating with Cincinnati Children's Hospital Medical Center and has enrolled three patients in such trials in the past year. "Targeted therapy has fundamentally shifted the way we think about treating cancer," Dr. Rush notes. Sickle Cell Program Prasad Bodas, MD, is Director of Akron Children's Leukemia and Regional Sickle Cell Programs. A member of Akron Children's team for the past four years, Dr. Bodas is a graduate of Case Western Reserve University School of Medicine. He joined Akron Children's after completing a fellowship at Rainbow Babies & Children's Hospital in Cleveland, where sickle cell disease was a primary interest. About one in 400 African Americans has sickle cell disease. In addition to the physical impact — greater susceptibility to infection, anemia and pain — poorly managed sickle cell disease can have emotional and social impacts, such as making it more difficult to graduate from school or hold a job. "The unemployment rate among people with sickle cell disease is estimated to be as high as 50 percent," says Dr. Bodas. Ohio has long been ahead of the curve when it comes to recognizing and address- ing problems associated with sickle cell. The state started screening newborns for sickle cell disease in 1990, 10 years ahead of the requirement for all 50 states. Today, area babies with a positive screening result are immediately referred to Akron Children's for early intervention. "We make sure these babies get the support they need to thrive. They go on antibiotic prophylaxis, and their parents learn how to manage their medical care. It's important for families to understand the child's care plan and when to seek immediate care, especially during the high- risk period up to age 5," says Dr. Bodas. Today, a growing number of children are being treated with hydroxyurea, a chemotherapy drug found in the 1960s to have significant effects on red blood cells. By the 1990s, hydroxyurea was the standard of care for adults with sickle cell disease. By 2011, it had become the standard for babies, as well. "Hydroxyurea is highly underused," says Dr. Bodas. "Akron Children's increased its use of the drug, going from three patients just four years ago to more than 50 today. That's nearly two-thirds of eligible patients." The success of hydroxyurea treat- ment for sickle cell at Akron Children's prompted Dr. Bodas and fellow Nicholas McGregor, MD, to help launch a sickle cell clinic in Port-Au-Prince, Haiti, where the disease is twice as common as it is in the U.S. — affecting one in 200 people. In addition to sharing comprehensive care guidelines, the project will introduce a clinical trial in Haiti that provides hydroxy- urea as part of routine sickle cell care. While hydroxyurea is a powerful treat- ment option, the only cure for sickle cell disease remains bone marrow transplanta- tion. Although transplants carry their own set of risks, Dr. Bodas says the youngest patients are the most likely to do well. Five Akron Children's patients have now undergone bone marrow transplants for sickle cell disease with good results. "It's important for patients with sickle cell disease and people with sickle cell trait to be seen at a multidisciplinary, family- centered program where they can find comprehensive support for the medical and social aspects of the disease, as well as have access to hydroxyurea and bone marrow transplant referrals," says Dr. Bodas. He also recommends education and genetic counseling for those with sickle cell trait, as new research shows they may be at increased risk for sudden death. Hemostasis and Thrombosis Center John Fargo, DO, directs Akron Children's Hemostasis and Thrombosis Center (HTC). He came on board in 2013 and is the new- est member of the childhood cancer and blood disorders team. Dr. Fargo attended the University of New England College of Osteopathic Medicine, followed by a residency at Phoenix Children's Hospital Prasad Bodas, MD, is Director of Akron Children's Leukemia and Regional Sickle Cell Programs. COV ER FE AT UR E PHOTO © JOE SMITHBERGER, SMITHBERGER PHOTOGRAPHY, NORTH CANTON, OHIO 1 0 | Cleveland/Akron/Canton MD NEWS ■ M D N E W S . CO M ■ N OV E M B E R / D E C E M B E R 2 0 1 5

Articles in this issue

Archives of this issue

view archives of MDNews - Cleveland-Akron-Canton - November/December 2015